PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, March 13, 2024 -- PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe...

Related Keywords

Boston ,Massachusetts ,United States ,James Mcarthur ,Laurence Watts ,Sarah Sutton ,Nasdaq ,Pepgen Inc ,Drug Administration ,Gilmartin Group ,Orphan Drug Act ,Rare Pediatric Disease ,Orphan Drug ,Enhanced Delivery Oligonucleotide ,Duchenne Muscular Dystrophy ,Private Securities Litigation Reform Act ,